A multi-center open-labeled study of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma, or chronic lymphocytic leukemia in Chinese population.
The purpose of this study is to investigate the efficacy and safety of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma (MM), low-grade non-Hodgkin's lymphoma (NHL), and chronic lymphocytic leukemia (CLL). From December 2005 to November 2006, the patients with MM, low-grade NHL, and CLL were enrolled in this study, male or female, aged > or = 18 years, transfusion-dependant, and receiving anti-neoplasia chemotherapy. Recombinant human erythropoietin-beta was used in this study with the dose initiated at 150 IU/kg, thrice a week, subcutaneously. The total treatment duration was 12 weeks. The primary endpoint of the study is response rate (RR), which is defined as hemoglobin increasing > or = 2 g/dL comparing to baseline level, or returning to normal range, without any transfusion within 6 weeks of evaluation. Fifty out of 82 (64.6%) patients enrolled in this study responded to the treatment and 29 patients had no response. Hypertension (12.2%) is the most common adverse effect; however, all the adverse events were mild, categorized in NCI grade I or II. We conclude that recombinant erythropoietin-beta was effective in the treatment of anemia of the patients with MM, NHL, and CLL, as well as it is well-tolerated.
Yang
Shen
S
Department of Hematology, Ruijin Hospital, Shanghai JiaoTong University, School of Medicine, No.197 Ruijin Road II, Shanghai, 200025, China. shen_yang@126.com.
Jun
Ma
M
Department of Hematology, Harbin Institute of Hematology, Harbin, China.
Hong-Li
Zhu
Z
Department of Hematology, Chinese PLA General Hospital, Beijing, China.
Jian-Min
Wang
W
Department of Hematology, Changhai Hospital, Shanghai Second Military Medical University, Shanghai, China.
Chun
Wang
W
Department of Hematology, Shanghai First People's Hospital, Shanghai JiaoTong University, Shanghai, China.
Lu-Gui
Qiu
Q
Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yong-Qiang
Zhao
Z
Department of Hematology, Peking Union Medical College Hospital, Beijing, China.
Jun
Zhu
Z
Beijing Cancer Hospital, Beijing, China.
Jian
Hou
H
Department of Hematology Changzheng Hospital, Shanghai Second Military Medical University, Shanghai, China.
Zhi-Xiang
Shen
S
Department of Hematology, Ruijin Hospital, Shanghai JiaoTong University, School of Medicine, No.197 Ruijin Road II, Shanghai, 200025, China.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology*; D044466:Asian People; D004921:Erythropoietin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D007501:Iron / Q000097:blood; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications; D008228:Lymphoma, Non-Hodgkin / Q000150:complications; D008232:Lymphoproliferative Disorders / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications; D011994:Recombinant Proteins; D016896:Treatment Outcome
D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin; D005293:Ferritins; D007501:Iron